Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
PHOENIX–(BUSINESS WIRE)–Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.
This groundbreaking therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history. This personalized medicine approach, focusing on a single high-risk patient, demonstrates the company’s dedication to innovative, tailored healthcare solutions.
Tim Warbington, CEO of Creative Medical Technology Holdings, Inc. shared his vision: “This is a historic moment. CELZ-201, developed after extensive research, represents our commitment to changing the T1D landscape. FDA clearance for this therapy underscores our drive to pioneer new pathways in disease prevention. Where there are no current treatments, we are hoping to provide new options.”
CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level. It embodies hope for high-risk individuals, offering a proactive defense against T1D development. This aligns with the company’s ethos of addressing diseases before they manifest, leveraging cutting-edge science for preventative care.
Timothy Warbington added, “CELZ-201 symbolizes our dedication to safe, innovative treatments that have the power to change lives. This therapy is just the beginning of our journey to reshape the future of medical care for at-risk populations globally.”
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a biotechnology company dedicated to the advancement of identifying and translating novel immediately deployable FDA registered biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology, and orthopedics and is traded on NASDAQ under the ticker symbol CELZ. For further information about the Company, please visit www.creativemedicaltechnology.com.
Special Note Regarding Forward Looking Statements
NASDAQ Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
Contacts
Company Contact
Creative Medical Technology
IR@CreativeMedicalTechnology.com
Investor Relations
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
Conor Rodriguez, Analyst
crodriguez@equityny.com
